NEJ026 trial: progression-free survival benefit is not enough

Lancet Oncol. 2019 Jul;20(7):e344. doi: 10.1016/S1470-2045(19)30397-3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Bevacizumab
  • Carcinoma, Non-Small-Cell Lung*
  • Disease-Free Survival
  • ErbB Receptors
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms*
  • Progression-Free Survival

Substances

  • Bevacizumab
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors